Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to speed on key events from the week. For those of you interested to read a bit more, we provide links to the source articles.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Week of August 03, 2026
For the week, the public indexes were UP, with the S&P +3.6% & DOW moving +3.0%. For the year both remain UP +13.1% and +11.7% respectively. The XBI (the biotech index) comes in UP +7.0% for the week and remains +29.6% for the year.
This week in biotech saw several major FDA approvals, significant financings, and strategic shifts among leading companies. The FDA cleared new therapies for melanoma, narcolepsy, and influenza, while two large biotech IPOs and a notable acquisition highlighted ongoing investor interest. Meanwhile, companies addressed clinical safety signals and restructured pipelines, and a new CDC director was confirmed, ending a year-long leadership gap.
FDA Approval
Replimune received accelerated FDA approval for its melanoma drug following two prior rejections. The decision was supported by an advisory panel that disagreed with earlier FDA staff concerns.
This approval provides a new treatment option for advanced melanoma patients and marks a significant regulatory milestone for Replimune after earlier setbacks.
FDA Approval
The FDA approved Takeda’s narcolepsy drug Orzeyful, an orexin receptor agonist, paving the way for a new class of treatments for sleep disorders.
Orzeyful’s approval introduces a novel mechanism for managing narcolepsy and potentially other neurologic conditions, addressing unmet needs and expanding the sleep disorder market.
FDA Approval
Moderna’s influenza vaccine, the first flu shot made with mRNA technology, was approved by the FDA for older adults. The approval followed an initial refusal to review, which was later reversed after leadership changes at the FDA.
This marks a significant step for mRNA technology beyond Covid-19 vaccines, potentially broadening the impact of mRNA-based therapeutics.
M&A
Tarsus announced the acquisition of Alkeus for up to $800 million, gaining a late-stage therapy for Stargardt disease.
The deal highlights continued M&A activity in rare ophthalmology and brings a promising therapy for a currently underserved patient population.
Financing/IPO
Latigo completed an IPO raising nearly $350 million to fund the development of non-opioid, ion-channel-blocking pain medications.
This large IPO reflects renewed investor confidence in biotech and supports the development of alternatives to opioid pain treatments.
Financing/IPO
Braveheart Bio debuted on the Nasdaq with an upsized IPO expected to raise $382.5 million, becoming the 22nd biotech to go public this year. The funds will support late-stage development of its lead therapy for hypertrophic cardiomyopathy.
The offering highlights a resurgence in biotech IPO activity and provides capital for advancing new cardiovascular therapies.
Financing
LifeMine secured $263 million in funding to develop a new drug for preventing organ transplant rejection, discovered by mining fungal genomes.
The financing demonstrates strong investor interest in innovative immunology approaches and supports the development of potentially safer transplant therapies.
Leadership/Policy
Erica Schwartz was confirmed as the next director of the CDC, filling a vacancy that lasted nearly a year.
Her appointment restores permanent leadership at a critical public health agency during a period of organizational transition.
Clinical Data/Safety
Intellia found that a specific HLA gene allele is linked to severe liver enzyme elevations in patients treated with its ATTR gene therapy. The company is sharing these findings with regulators and updating trial protocols.
Identifying a genetic risk factor helps address safety concerns in gene editing and may enable risk mitigation strategies for future gene therapies.
Restructuring/Clinical
Sanofi suspended a Phase 2 study in non-cystic fibrosis bronchiectasis as part of a broader portfolio review initiated by its new CEO. The pause was attributed to strategic business reasons rather than safety concerns.
The move signals a shift in Sanofi’s R&D priorities and reflects ongoing efforts by major pharma companies to optimize pipelines for long-term value.
Thank you for reading BowTiedBiotech. Help us grow our community and earn FREE subscription to BowtiedBiotech - sharing is caring!
CONCLUSION
There you have it, another week of your Weekly Biotech News Fix. We hope you enjoyed it, please drop a comment with any feedback you may have.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
SUBSCRIBE TO PODCAST HERE:
Sundays and Mondays are under the paid umbrella, everything else is FREE. It is $11.99/month and we encourage you to support our efforts. It keeps us motivated to keep producing the hybrid science and business biotech focused content you will not find anywhere else all in the same place.
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.